Abstract: A method of identifying an antiviral agent effective against viruses, which utilize ?1 programmed ribosomal frameshifting is provided. The method includes providing cells harboring a ?1 frame plasmid including a translation start site followed by a ?1 ribosomal frameshifting signal followed by a reporter gene which is in a ?1 frame relative to the translation start site. The method further includes contacting the cells with a test agent; and measuring the activity of the reporter gene in the presence of the test agent, wherein the reporter gene activity is dependent on ?1 ribosomal frameshifting.

Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.

Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.

Abstract: An isolated multiprotein complex of S. cerevisiae components is provided that is effective to modulate peptidyl transferase activity during translation. This complex includes a Modulator of Translation Termination protein (Mtt1p, also referred to as helicase B), a Upf1 protein, a peptidyl eukaryotic release factor 1 (eRF1) and a peptidyl eukaryotic release factor 3 (eRF3).

Abstract: This invention provides a method of modulating translation termination efficiency of mRNA and/or promoting degradation of abberant transcripts. Also, this invention provides a method of screening for a drug active involved in enhancing translation termination and a method for identifying a disease state involving defective the protein complex.

Abstract: This invention provides a method for modulating the efficiency of translation termination of messenger RNA. Also provided are methods of screening for compositions and agents capable of modulating translation termination.

Abstract: Provided are novel methods and assays to identify agents and compositions that modulate the ability of the eukaryotic surveillance complex to effect translation termination and degradation of aberrant mRNA.

Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.

Abstract: This invention provides a method of modulating translation termination efficiency of mRNA and/or promoting degradation of abberant transcripts. Also, this invention provides a method of screening for a drug active involved in enhancing translation termination and a method for identifying a disease state involving defective the protein complex. This invention provides a purified complex comprising an amount of a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) effective to modulate translation termination. Further, this invention provides an expression vector which comprises a nucleic acid encoding a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) operably linked to a regulatory element.

Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.